OmniAb

OmniAb

OmniAb originated in 2015 as a wholly owned subsidiary of Ligand Pharmaceuticals, later separating into an independent public company through a business combination with Avista Public Acquisition Corp. II in November 2022. The firm is led by CEO Matt Foehr, who previously served as president and chief operating officer of Ligand. OmniAb's business model does not develop its own drugs; instead, it generates revenue through technology access fees and downstream milestone payments and royalties on partner programs that use its antibody discovery platforms. The platform portfolio rests on three core transgenic animal technologies: OmniMouse, OmniRat, and OmniChicken. Partners engineer these animals to produce fully human antibodies, which they then screen against targets of interest. Since inception, the platforms have been licensed to over 80 biopharmaceutical companies and academic institutions, including Merck, Pfizer, and Gilead. As of public filings, more than 300 active programs are underway, with over 30 having progressed into clinical development. The royalty stream is geographically diversified, with partner labs and clinical sites spanning North America, Europe, and Asia-Pacific. OmniAb operates a lean model. Headcount is not disclosed, but the firm runs its discovery engines from a centralized lab in Emeryville, California, with a smaller footprint in Basel, Switzerland. The firm has not raised traditional venture funding; its post-spin capitalization came from the de-SPAC transaction and existing royalty receipts. In 2024, OmniAb expanded its platform partnership with Vaccitech, adding a bispecific antibody program to the existing collaboration (per company announcements, July 2024). The firm also maintains a passive minority stake in multiple partner entities, providing an additional, albeit modest, equity upside layer. OmniAb is structurally distinct from both traditional biotech and investment managers: it is a publicly traded royalty company with a Discovery-as-a-Service model. Unlike a typical family office or venture fund, it does not deploy capital into portfolio companies. Instead, it provides the intellectual property tooling upfront and collects a share of success downstream, creating a capital-light, highly diversified biologics exposure. The leadership succession post-Ligand spin, with Foehr retaining the CEO role and an independent board overseeing strategy, positions the vehicle as a pure-play bet on biologic drug discovery without the binary risk of a single-program biotech.